|
|
|
|
The primary reasons for withdrawal of tacrine-treated patients were asymptomatic liver transaminase elevations(28%)and gastrointestinal complaints(16%).These adverse events were reversible on discontinuation of treatment,and many patients were able to restart tacrine.Tacrine produced statistically significant,dose-related improvements on objective performance-based tests,clinician-and caregiver-rated global evaluations, and measures of quality of life.There was no evidence that the large number of patients withdrawals biased the overall conclusions of the study. |
|